One in 10 clinics in SA will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines ...

By Dickens Okinyi Kenya’s ongoing fight against HIV has entered a new phase with the roll out of Lenacapavir, a groundbreaking long-acting HIV prevention and treatment drug, set to take place in 2026.

The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...

Zimbabwe has been chosen as one of 10 countries globally to roll out lenacapavir, the world's first twice-yearly injectable ...

The AHF Global Public Health Institute for Latin America and the Caribbean, in collaboration with the National Institute of ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

O AHF Global Public Health Institute para a América Latina e Caribe, em parceria com o Instituto Nacional de Saúde Pública do ...

Source: ‘Miracle’ HIV shot rollout in Zimbabwe sparks debate – DW – 10/16/2025 Zimbabwe is among 10 nations rolling out ...

In response, the South African National Treasury allocated R750 million in emergency funding to prevent service interruptions ...

Zimbabwe is among 10 nations rolling out lenacapavir, a twice-yearly HIV prevention shot. "We are excited to announce that ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

ViiV found by GSK (GSK) and Pfizer (PFE) are in focus as its long acting HIV PrEP therapy cabotegravir outperforms Gilead's lenacapavir in Phase 1 trial. Read more here.